Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Mar 11;11(3):e0150955. doi: 10.1371/journal.pone.0150955

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 Steuer et al

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Fig 5 — (a) Metabolite ratio of R-DHMA 3-sulfate to R-MDMA in placebo-pretreated CYP2D6 extensive metabolizers (EM), intermediate metabolizers (IM), and EMs after pretreatment with bupropion. The data represent single measurements of 13 participants (placebo-pretreated EMs and bupropion-pretreated EMs) or three IMs at different time points after MDMA administration (0.33–24 h). ⁺⁺⁺p < 0.001, significant difference between placebo+MDMA-treated CYP2D6 IMs and bupropion+MDMA-treated CYP2D6 EMs (Mann-Whitney test). (b) Metabolite ratio of R-DHMA 3-sulfate to R-MDMA in CYP2D6 EMs, IMs, and EMs after pretreatment with bupropion over time. Black circles and solid lines represent extensive metabolizers (EM). Triangles and dotted lines represent intermediate metabolizers (IM). Open circles and solid lines represent EMs after pretreatment with bupropion. The data are expressed as mean and SEM.